Immunosuppression in uveitis

Ophthalmol Clin North Am. 2002 Sep;15(3):395-404, viii. doi: 10.1016/s0896-1549(02)00036-6.

Abstract

The treatment of ocular inflammatory disease continues to be a major challenge as the clinician tries to balance the risks and the benefits of immunosuppressive therapy. Currently, corticosteroids, antimetabolites, and calcineurin inhibitors are the most commonly used agents. Biologically active agents including monoclonal antibodies, however, provide a promising new form of treatment that can target the immune system more specifically and more safely. Long-term studies are needed to determine the role of biologic agents in the treatment of uveitis.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunosuppression
  • Immunosuppressive Agents / therapeutic use*
  • Uveitis / drug therapy*

Substances

  • Immunosuppressive Agents